Goal
Provide a bioavailable source of organic silica to treat arthritis, bone and connective-tissue disorders and other health ailments.
Problem
Deficiency of organic (bioavailable) silica in the human body, which is linked to impaired bone calcification, cartilage degradation and joint diseases such as arthritis.
Concept Summary
Le Ribault proposes that a water-soluble organic silica preparation (named G5 or OS5) can be ingested as a tonic to replenish the body's silicon stores, thereby supporting bone, cartilage and connective-tissue health. The therapy is claimed to have cured psoriasis, treated arthritis and benefited thousands of patients despite lack of formal clinical trials.
Principles
- Bioavailable organic silica supplementation
- Silicon as an essential nutrient for bone and cartilage formation
- Oral delivery of a water-soluble silica solution
Scientific Domains
Materials
- Organic silica (silicon dioxide with carbon content)
- Water
Mechanisms of Action
- Provides soluble silicon that can be incorporated into collagen and bone matrix
- Supports calcification processes in bone and cartilage
- Modulates connective-tissue metabolism
Applications
- Arthritis treatment
- Bone and cartilage regeneration
- General connective-tissue health
Claimed Performance
Cured psoriasis in the inventor; treated arthritis and other ailments in over ten thousand patients; reported bone and cartilage growth stimulation.
Experimental Evidence
Anecdotal reports of >10 000 patients treated with topical poultices and oral G5 tonic; no peer-reviewed clinical trial data presented.
Limitations
- No independent, peer-reviewed clinical trials
- Potential toxicity of early formulations
- Regulatory approval absent
Red Flags
- Claims based on anecdotal evidence only
- Narrative of persecution and lack of scientific scrutiny
- No documented replication by independent researchers
